anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, immunology, pharmacy. SUBSTANCE: invention relates to using monoclonal antibodies. Invention reports primatized monoclonal antibodies or their fragments that bind specifically its human antigen CD80 and inhibit binding antigen CD80 with CD20 but don't inhibit binding antigen CD80 with CTLA-4 and comprise variable domains of simian monoclonal antibody 16C10 light and heavy chains with amino acid sequence represented in Fig. 5a and 5b, respectively, either simian monoclonal antibody 7C10 with amino acid sequence represented in Fig. 3a and 3b, respectively, and comprise constant domains of human immunoglobulin light and heavy chains. These antibodies and pharmaceutical compositions comprising thereof can be used as specific immunosuppressants in treatment of autoimmune diseases and for prophylaxis in rejection of organs to be transplanted. EFFECT: improved treatment method, valuable biological and medicinal properties of antibody. 14 cl, 10 dwg, 11 ex
This project is a twofold exploration of the functions of the premotor cortex, concerning, on the one hand, its role in conscious visual perception, and on the other hand, the part it may play in the perception and imitation of other people's movements. Healthy subjects will be compared with subjects suffering from focal lesions within the premotor cortex, on two tasks: in the first task, the subjects will have to make a decision concerning the absence or presence of a visual item in their field of vision. They will make (virtual) bets based on the subjective certainty of their perceptions - they will be told that these bets are purely virtual, and will not result in any financial gain or loss. This study will help us understand the contribution of the prefrontal cortex to subjective weighing of perceptual certainty. In the second task, the subjects will imitate a finger movement, based either on a fixed picture, or on a short motion picture. Previous studies have shown that whether the movement is copied from a fixed picture or a moving picture changes reaction times and types of mistakes. Neuroimaging studies have shown that a premotor area is involved in this effect. The comparison of brain-damaged and healthy subjects will tell us what exactly the contribution of the prefrontal consists in.
SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
Participants will receive litifilimab SC Q4W from Week 0 to Week 20, with an additional dose of litifilimab at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive litifilimab during the ETP from Week 24 to Week 48, with an additional dose of litifilimab-matching placebo at Week 26.
The present invention discloses a qi and blood deficiency type migraine treating drug and a preparation method thereof. The bulk drugs in the qi and blood deficiency type migraine treating drug comprise: vitis flexuosa thunb, divaricate serpentroot herb and root, scorzonera austriaca willd, codonopsis pilosula, fruit of highland barley malt, atractylodes macrocephala, medicago archiducis-nicolai g.sirjaev, fissistigma oldhamii (hemsl.) merr, common yam rhizome, amorphophallus konjac, acanthopanax senticosus, dodder, radix rehmanniae preparata, musk, tuckahoe, angelica, dried large yellow croaker, cynanchum otophyllum, polygonum coriaceum, fructus ligustri lucidi, dioscorea althaeoides r. knuth, saposhnikovia divaricata, ligusticum chuanxiong hort, sambucus williamsii, angelica dahurica, fewleaf schnabelia herb, ligusticum sinense oliv, asarum, lepidogrammitis rostrata, prunella vulgaris, buddleja officinalis maxim, malva rotundifolia, chrysanthemum, viola philippica cav, cayratia japonica (thunb.) gagnep, meconopsis quintuplinervia regel, licorice root, pasta ulmi, phymatodes lucida (roxb.)ching, gymnema, hao tian pao root, fructus lagenariae gourdae stem, and amphibious crab. The qi and blood deficiency type migraine treating drug of the present invention has beneficial effects of qi and blood nourishing, qi and blood deficiency type migraine treating, syndrome differentiation treatment from the whole body, strong targeting property, direct efficacy on lesions, short treatment course, good treatment effect, low toxic-side effect, easy administration, recurrence resistance after cure, drug resistance generation resistance of patients, immunity improving, simple pharmaceutical production process, low cost and the like.
This invention relates to a technique method that enhancing acyclovir dissolve in injection. In this invention acyclovir is dissolved in water or glucose water solution, poly sorbit ester 80, polyethylene glycol 400, are added in the injection, the content of acyclovir is 0.1-0.3%, content of poly sorbit ester 80 and polyethylene glycol 400 are both 2-8%. This invention resolves a problem that acyclovir doesn't dissolve in water or glucose water solution or bring a lot of precipitations when temperature is lower than 20 degree centigrade, especially than 5 degree centigrade. So the defect of serious side effect of illness state delay can be avoided. poly sorbit ester 80 and polyethylene glycol 400 has solubilization character to make acyclovir more easily dissolve in water or glucose water solution, so the solubility of acyclovir can be greatly improved when temperature is lower than 20 degree centigrade, especially than 5 degree centigrade. So it is propitious to transportation, storage and using of acyclovir injection.
Due to the complications like intensive care unit-acquired weakness, critical illness polyneuropathy and neuropsychiatric disease of critical care, many organizations focus on rehabilitation in critically ill patients' management. Despite the good outcomes from papers, there are debatable issues of method, safety and efficacy of rehabilitation. The investigators developed an early rehabilitation program (ERP) in our surgical ICU management and assessed safety and efficacy of it.

The ERP started in November 2014 in our 14-bed surgical ICU in Asan Medical Center. The investigators focused on early and 5-step rehabilitation program for patients who were admitted to SICU for at least 3 days. The investigators enrolled 69 patients (pre-ERP group) for 6 months before November 2014 and 62 patients (post-ERP group) for 6 months 1 year after the ERP started. The main measures were safety issues, delirium days, 28-d ventilator free-days, 28-d ICU free-days, hospital length of stay (LOS), ICU mortality, in-hospital mortality and 1 year mortality.
The present invention relates to a liquid-solid mixed lipid nano-slow release system for cosmetics and a preparation method thereof. The release system is composed of nanoparticles constituted by liquid lipid and solid lipid and at least one active ingredient coated in the nanoparticles. The preparation method includes: (1) dispersing a mixing carrier of the solid lipid and the liquid lipid to an organic solvent, adding the active ingredient, and heating in a water bath to dissolve the solid lipid to get an organic phase solution; (2) formulating polyvinyl alcohol into an aqueous phase solution, and adjusting the pH to be acidic to get an aqueous phase solution; and (3) adding the organic phase solution to the aqueous phase solution under the conditions of mechanical agitation with stirring to get a mixed lipid dispersion liquid which is then centrifuged and separated to obtain the nano-slow release system. The nano-slow release system is simple in preparation method and high in stability. The dimensions of the particles are in nanoscale, and the particle size is controllable. The entrapment efficiency of the liquid-solid mixed lipid nanoparticles has been greatly improved than simple solid nanoparticles.
In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30–59 mL/min) renal impairment, the combined exposure (AUCinf,u) of abrocitinib and its two active metabolites, M1 and M2, is increased compared to patients with normal renal function (eGFR ≥90 mL/min) [see Clinical Pharmacology (12.3)]. This may increase the risk of adverse reactions such as infections.

CIBINQO is not recommended for use in patients with severe renal impairment and ESRD including those on renal replacement therapy [see Dosage and Administration (2.3)].

A dosage reduction in patients with moderate renal impairment is recommended. No dosage adjustment is required in patients with mild renal impairment (eGFR 60–89 mL/min) [see Dosage and Administration (2.3)].

CIBINQO has not been studied in subjects on renal replacement therapy. In Phase 3 clinical trials, CIBINQO was not evaluated in subjects with atopic dermatitis with baseline creatinine clearance values less than 40 mL/min.
In the recent sepsis-definitions, myocardial depression is included in the definition of severe sepsis, indicated as lowered cardiac index or echocardiographically documented cardiac dysfunction. Myocardial dysfunction occurs in greater than 50% of patients with severe sepsis and septic shock. In this context, B-type natriuretic peptid (BNP) from ventricular myocytes may serve as a surrogate biomarker for the evaluation and quantification of myocardial dysfunction. Biologically active BNP is cleaved into inactive NT-proBNP, which is supposed to be a better marker of myocardial dysfunction and prognosis in patients with severe sepsis and septic shock. However, severity of illness dependent association of myocardial dysfunction, especially left ventricular diastolic function, dosage of norepinephrine, NT-proBNP and biomarker plasma concentrations has not been systematically investigated in postoperative/posttraumatic patients in septic shock or volume-deficiency/hemorrhagic shock. Moreover, data regarding NT-proBNP plasma concentrations and renal function in postoperative/posttraumatic patients are sparse. Therefore, this prospective observational study will enroll n= 200 postoperative/posttraumatic patients to monitor longitudinally NT-proBNP, biomarkers, and cell surface markers on leukocytes to find out whether there is a discriminating pattern of myocardial dysfunction, NT-proBNP and biomarkers in patients with non-septic or septic shock, respectively, and with beneficial or harmful outcome.
Ectopic/accessory liver tissue is a rare developmental anomaly thought to be due to abnormal development of the liver during embryogenesis. Most patients with ectopic liver tissue are asymptomatic, and the condition is usually discovered incidentally during intraabdominal surgery or autopsy. In rare symptomatic cases, patients' presentations can range from mild liver function test abnormalities to severe abdominal pain or discomfort secondary to torsion and ischemia. Here, we report 2 patients with ectopic liver tissue identified incidentally during cholecystectomy: one with histologic manifestations of sickle cell congestion and the other with steatohepatitis. A possible relationship between ectopic liver tissue and gallbladder and biliary diseases, such as cholecystitis, has been proposed. To the best of our knowledge, ectopic liver tissue with sickle cell congestion has not been reported previously.
Dystroglycan (DG) is an extracellular matrix receptor consisting of an α- and a β-DG subunit encoded by the DAG1 gene. The homozygous mutation (c.2006G>T, p.Cys669Phe) in β-DG causes muscle-eye-brain disease with multicystic leukodystrophy in humans. In a mouse model of this primary dystroglycanopathy, approximately two-thirds of homozygous embryos fail to develop to term. Mutant mice that are born undergo a normal postnatal development but show a late-onset myopathy with partially penetrant histopathological changes and an impaired performance on an activity wheel. Their brains and eyes are structurally normal, but the localization of mutant β-DG is altered in the glial perivascular end-feet, resulting in a perturbed protein composition of the blood-brain and blood-retina barrier. In addition, α- and β-DG protein levels are significantly reduced in muscle and brain of mutant mice. Owing to the partially penetrant developmental phenotype of the C669F β-DG mice, they represent a novel and highly valuable mouse model with which to study the molecular effects of β-DG functional alterations both during embryogenesis and in mature muscle, brain and eye, and to gain insight into the pathogenesis of primary dystroglycanopathies.
PROBLEM TO BE SOLVED: To provide a method in which a poloxamer, a resin, and/or a tocopherol is/are fused, and the material that is to be treated is intimately dispersed with the fusion.SOLUTION: The material that is to be treated is coated with water to prevent hardening, and the spontaneously forming gel is homogenized. The obtained product is at least one poloxamer, a resin or a tocopherol, which is solubilized, dispersed, and stabilized therein. The fusion can be used for dissolving fats, peptides, resins, and all types of resinous materials, removing the resinous materials from surfaces, cleaning, and lubricating. If a vegetable substance is intimately dispersed in such a dissolved material, the dissolved material is cooled instead of being coated with water. The dissolved material turns brittle, and is finely ground and reduced to a diameter of less than 5 micrometers. The crystals of the dissolved material are then dissolved or dispersed in additional water and are added to the humus soil in order for the crystals to be absorbed by the plant via the roots thereof, or the crystals are sprayed directly to the part of the plant that lies above the ground.
BACKGROUND: Pediatric patients with kidney failure often experience cognitive delays. However, academic delay (being more than one grade level below age-appropriate grade, or in special education) after pediatric kidney transplantation (KTx) has not been explored. We sought to identify patient characteristics associated with a higher risk of academic delay 1 year post-KTx.
METHODS: We used the United Network for Organ Sharing (UNOS) database to identify children aged 6-17 years who received a primary KTx between 2014 and 2021 and had a functioning graft 1 year after KTx. The primary outcome was the patient's academic progress at 1 year post-transplant. The secondary outcome was change in academic progress between transplant and 1-year follow-up: onset of new delay, resolution of pre-existing delay, persistence of delay, or no delay at either timepoint. Binomial and multinomial mixed effects logistic regression models were used to predict each outcome based on patient characteristics.
RESULTS: The study included 2197 patients, of whom 14% demonstrated academic delay at 1 year post-KTx, 4% demonstrated a new onset of academic delay, 5% demonstrated a resolution of academic delay, and 10% demonstrated persistent academic delay. Patients undergoing transplantation at a younger age, receiving a deceased donor kidney, experiencing longer waitlist times, and undergoing KTx for vascular or other disease indications for KTx were more likely to experience academic delays, including new-onset academic delays.
CONCLUSIONS: Academic delays are frequently reported among pediatric KTx recipients. Additional academic support may help resolving or preventing academic delay for at-risk subgroups of children undergoing KTx.
Myocardial infarction (MI) is a critical global health challenge, with current treatments limited by the complex MI microenvironment, particularly the excessive oxidative stress and intense inflammatory responses that exacerbate cardiac dysfunction and MI progression. Herein, a mannan-based nanomedicine, Que@MOF/Man, is developed to target the inflammatory infarcted heart and deliver the antioxidative and anti-inflammatory agent quercetin (Que), thereby facilitating a beneficial myocardial microenvironment for cardiac repair. The presence of mannan on the nanoparticle surface enables selective internalization by macrophages rather than cardiomyocytes. Que@MOF/Man effectively neutralizes reactive oxygen species in macrophages to reduce oxidative stress and promote their differentiation into a reparative phenotype, reconciling the inflammatory response and enhancing cardiomyocyte survival through intercellular communication. Owing to the recruitment of macrophages into inflamed myocardium post-MI, in vivo, administration of Que@MOF/Man in MI rats revealed the specific distribution into the injured myocardium compared to free Que. Furthermore, Que@MOF/Man exhibited favorable results in resolving inflammation and protecting cardiomyocytes, thereby preventing further myocardial remodeling and improving cardiac function in MI rats. These findings collectively validate the rational design of an inflammation-targeted delivery strategy to mitigate oxidative stress and modulate the inflammation response in the injured heart, presenting a therapeutic avenue for MI treatment.
Patients receive eprenetapopt IV over 6 hours on days 1-4 and venetoclax PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
They are composed of 29 participants. After endodontic treatment, they will receive a simulation of the PBM session with all individual preparation involved, such as individual protection with goggles, and the sounds of the equipment (Laser Duo®, MMOptics, São Carlos, SP) will be recorded and played at the time of the session, but the equipment will not be activated.
PURPOSE:To obtain a hair tonic effective in promoting the growth of hair, exhibiting excellent hair-tonic effect and effective to alopecia by using various ester derivatives of nicotinic acid N-oxide as active component. CONSTITUTION:The objective hair tonic can be produced by using one or more kinds of the compounds of formula I [R is group of formula II, formula III (R<1> is H, 1-9C alkyl, OH, etc.; R<2> is H, OH, methoxy or halogen), dl-alpha-tocopheryl, group of formula IV, etc.] as an active component and properly compounding vitamin E, pantothenic acid, antibacterial agent, blood flow acceleration agent, refreshing agent, oil, drug, surfactant, colorant, perfume, antioxidant, ethanol, water, etc. The amount of the compound of formula I is 0.1-5.0wt.%. The compound of formula I can be produced by reacting nicotinic acid N-oxide with various alcohols in pyridine solvent in the presence of dicyclohexyl carbodiimide.
Rheumatoid arthritis (RA) is a multifaceted autoimmune disorder characterized by chronic inflammation and joint destruction. Recent research has elucidated the intricate interplay between gut microbiota and RA pathogenesis, underscoring the role of microbiota-derived metabolites as pivotal contributors to disease development and progression. The human gut microbiota, comprising a vast array of microorganisms and their metabolic byproducts, plays a crucial role in maintaining immune homeostasis. Dysbiosis of this microbial community has been linked to numerous autoimmune disorders, including RA. Microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), tryptophan derivatives, Trimethylamine-N-oxide (TMAO), bile acids, peptidoglycan, and lipopolysaccharide (LPS), exhibit immunomodulatory properties that can either exacerbate or ameliorate inflammation in RA. Mechanistically, these metabolites influence immune cell differentiation, cytokine production, and gut barrier integrity, collectively shaping the autoimmune milieu. This review highlights recent advances in understanding the intricate crosstalk between microbiota metabolites and RA pathogenesis and also discusses the potential of specific metabolites to trigger or suppress autoimmunity, shedding light on their molecular interactions with immune cells and signaling pathways. Additionally, this review explores the translational aspects of microbiota metabolites as diagnostic and prognostic tools in RA. Furthermore, the challenges and prospects of translating these findings into clinical practice are critically examined.
BACKGROUND: Candidemia is an opportunistic infection of intensive care units (ICUs) and causes morbidity and mortality. Multiple antibiotic exposure was found to be an independent risk factor for mortality and non-albicans candidemia (NAC) in candidemia patients.
AIM: The aim of this study was to determine the relationship between antibiotics and clinical features of patients with candidemia, and to determine the independent risk factors for hospital stay >50 days, 30-day mortality in hospital, candidemia types, and septic shock in candidemia patients.
METHODS: Patients were evaluated retrospectively for 5 years. A total of 148 candidemia cases were detected and included in the study. Characteristics of cases were defined and recorded. The relationship between qualitative data was determined by the χ2 test. Logistic regression analysis was used to determine the independent risk factors for hospital stay >50 days, 30-day mortality in hospital, candidemia types, and septic shock in candidemia patients.
RESULTS: The incidence of candidemia for 5 years was 4.5%. Candida parapsilosis was the most reported species with 65% (n=97). Linezolid and central venous catheters (CVC) were found to be independent risk factors for NAC. Carbapenems and cephalosporins were found in association to lower mortality. No antibiotics or characteristics were found to be independent risk factors for mortality. Some broad spectrum antibiotics and antibiotic combinations were found in relationship with hospital stay >50 days; however, none of them were found to be independent risk factors. Metisilin resistant staphylococcus aureus (MRSA) antibiotics, meropenem+linezolid piperacillin-tazobactam+fluoroquinolones and comorbidity were found in association with septic shock, although only piperacillin-tazobactam+fluoroquinolones and comorbidity were found to be independent risk factors for septic shock.
CONCLUSIONS: This study concluded that many antibiotics were safe for candidemia patients. However, clinicians should pay attention when prescribing linezolid or piperacillin-tazobactam and flouroquinolons concomitantly or sequentially for patients with candidemia risk factors.